# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Anne Samuel maintains Omnicell (NASDAQ:OMCL) with a Neutral and raises the price target from $26 to $37.
Full-Service, Scalable Solution Designed to Help Health Systems Establish and Continuously Optimize Centralized Medication Mana...
Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:OMCL) with a Equal-Weight and raises the price target from $...
B of A Securities analyst Allen Lutz maintains Omnicell (NASDAQ:OMCL) with a Buy and raises the price target from $34 to $44.
Barclays analyst Stephanie Davis upgrades Omnicell (NASDAQ:OMCL) from Underweight to Equal-Weight and raises the price targe...